Introduction
Acne is the most prevalent skin disease in the world, affecting 85% of adolescents and over 10% of adults [
1]. In the USA, it represents a tremendous economic burden with total costs exceeding $3 billion per year [
2]. Antibiotics are efficient against sensitive
Propionibacterium acnes, but resistance has developed due to monotherapy and overuse [
3]. Other treatments such as retinoids and benzoyl peroxide are limited by patient compliance due to undesirable side effects such as irritation [
4]. Benzoyl peroxide is highly effective as an antimicrobial in vitro [
5] and in vivo [
6], and it is a first-line drug for the treatment of acne due to its direct bactericidal and comedolytic properties. Although no known bacterial resistance has been reported to benzoyl peroxide [
7,
8], its side effects still limit its use. Thus, the need exists for new efficacious treatments with fewer side effects. Already, newer topical combination therapies have been developed to reduce the concentration of benzoyl peroxide through its combination with other anti-acne compounds [
9].
Resveratrol (3,5,4′-trihydroxystilbene) may be a useful anti-acne treatment. It is a potent antioxidant and anti-inflammatory compound that has been shown to have antineoplastic and wound-healing activities [
10]. It has been demonstrated to inhibit inflammatory markers activation protein-1 (AP-1) and nuclear factor-kappaB (NF-κB), both of which have been implicated in the formation of inflammatory acne lesions [
11]. Resveratrol is also antimicrobial, demonstrating antiviral, antifungal, antibacterial, and antiprotozoal activity [
12‐
14], and has been shown to inhibit keratinocyte proliferation, which contributes to follicular obstruction in the formation of acne lesions [
15]. Few studies have evaluated resveratrol’s application as a treatment for acne vulgaris, although one clinical study has previously demonstrated the potential efficacy of resveratrol in the treatment of acne vulgaris [
16]. Additionally, an in vitro study showed that resveratrol has antimicrobial activity against
P. acnes [
17].
The present study further investigated the potential of resveratrol as a treatment for acne. It sought to determine the in vitro effects of resveratrol on P. acnes growth and survival, while further assessing the antimicrobial mechanism of action of resveratrol and its cytotoxic effects. It also determined the efficacy of utilizing resveratrol as part of a combination therapy with benzoyl peroxide.
Methods
Reagents
Resveratrol and benzoyl peroxide were obtained from Sigma-Aldrich (St. Louis, MO, USA). The compounds were dissolved in dimethyl sulfoxide (DMSO) and diluted to 1% DMSO in experiments, to minimize the effect of DMSO.
Antibacterial activity of resveratrol was determined by colony-forming unit (CFU) assays.
P. acnes ATCC (American type cell culture) strain 6919 (a ribotype 1 [
18] MLST4 1A
1 strain [
19]) was grown anaerobically at 37 °C in reinforced clostridial media (Oxoid, Basingstoke, Hampshire, UK) for 3 days and collected in the late exponential phase of growth by centrifugation. Bacteria were washed with pH 7 sodium phosphate buffer supplemented by 0.03% trypticase soy media and quantified by reading with a spectrophotometer at 600 nm and applying a conversion of 1 × 10
8 bacteria = 1 absorbance unit. Approximately, 1.33 × 10
6 CFUs of bacteria were then added to 1 mL reinforced clostridial media. Samples were incubated anaerobically at 37 °C, with aliquots periodically withdrawn and plated on brucella agar with 5% sheep blood supplemented with hemin and vitamin K (Remel, Lenexa, KS, USA). Plates were incubated anaerobically at 37 °C for 3 days, and individual
P. acnes colonies were counted to determine the concentration.
Electron Microscopy
Propionibacterium acnes at 107 CFU/mL were incubated with either 1 mg/mL of resveratrol or benzoyl peroxide for 24 h. Bacteria were washed three times with phosphate buffered saline (PBS) and resuspended in PBS with 2% glutaraldehyde. Samples were fixed for 5 min with 0.05% OsO4, dehydrated in graded ethanol, and embedded in Eponate 12 (Ted Pella, Redding, CA, USA). A Reichert-Jung Ultracut E ultramicrotome™ (Leica, Buffalo Grove, IL, USA) was used to cut 60–70 nm slices which were picked up on formvar-coated copper grids. Uranyl acetate and Reynolds lead citrate were used for staining, and stained samples were visualized at 80 kV on a JEOL 100CX electron microscope™ (Peabody, MI, USA).
MTS Assay
Blood was drawn from healthy human volunteers recruited by the laboratory with no skin conditions, including acne, and who had not suffered any illness within 2 weeks of the blood draw date. Peripheral blood mononuclear cells were isolated by use of a Ficoll-Paque (Pharmacia, New York, NY, USA) gradient and allowed to adhere for 2 h in RPMI media (Gibco, Grand Island, NY, USA) supplemented with 1% fetal bovine serum (FBS) (Omega Scientific, Tarzana, CA, USA) in 96-well plates (Costar, Tewksbury, MA, USA). Cells were washed 3× with Roswell Park Memorial Park Institute (RPMI) media to obtain adherent monocytes. Monocytes were then incubated at 37 °C in 100 μL RPMI media supplemented with 10% FBS. The HaCaT cell line of human keratinocytes was cultured in 100 μL HaCaT media and incubated at 37 °C in 96-well plates (Costar). To evaluate human monocyte and human keratinocyte viability after incubation with resveratrol or benzoyl peroxide, 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) cytotoxicity assays were performed. After 16 h of incubation with resveratrol or benzoyl peroxide, 20 μL MTS assay reagent (Promega, Madison, WI, USA) was added to each well, and the monocyte and keratinocyte cells were allowed to incubate for ~4 h at 37 °C. The 490 nm absorbance of each well was then determined using a microtiter plate reader, with absorbance proportional to the number of viable monocyte and keratinocyte cells in each treatment, as previously described [
20]. Student’s
T test was used for statistical analysis to determine if differences between resveratrol and benzoyl peroxide-treated cells were significant.
Compliance with Ethics Guidelines
Study protocol for withdrawal of blood from healthy volunteers was approved by the Institutional Review Board at the University of California, Los Angles. All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki declaration of 1975, as revised in 2000 and 2008. Informed consent was obtained from all patients for being included in the study.
Discussion
Acne vulgaris is the most common skin disease, affecting millions of people worldwide [
21].
Unfortunately, bacterial antibiotic resistance and severe side effects limit the efficacy of current treatments [
22].
Resveratrol has a favorable safety profile and is an anti-inflammatory and antimicrobial compound. Thus, this study investigated the potential of resveratrol as an antibacterial agent for the treatment for acne vulgaris.
The results from this study demonstrated the strong antibacterial activity of resveratrol at concentrations of at least 50 μg/mL (Fig.
1). These findings are consistent with prior studies which have demonstrated inhibition of
P. acnes biofilm formation at slightly higher concentrations of 200 μg/mL [
23]. By further investigating the nature of this antibacterial activity, we found that resveratrol is bacteriostatic in nature, possessing strong inhibitory activity that limits the growth of
P. acnes (Fig.
2a). Its bactericidal activity was relatively weak in terms of reduction of viable bacteria, but the antibacterial activity was sustained over time. This indicates that resveratrol creates a gradual disruption of normal bacterial cellular function, resulting in cell death over a period of several days. Our findings suggest that resveratrol reaches a critical concentration around 50–75 μg/mL, at which point a threshold for major growth inhibition is passed and resveratrol becomes bactericidal for a sustained period. In contrast, benzoyl peroxide’s bactericidal activity was strong initially, but was not sustained beyond the first 24 h (Fig.
2b). This is in accordance with benzoyl peroxide’s mechanism of action, whereby free radicals are formed via symmetrical fission, resulting in a short half-life [
24].
When both resveratrol and benzoyl peroxide were combined, benzoyl peroxide’s strong bactericidal effect coupled with resveratrol’s high inhibitory activity resulted in low levels of bacteria throughout the experiment (Fig.
2c). Thus, this combination shows promise for clinical treatment of acne vulgaris.
Electron microscopy of
P. acnes treated with resveratrol revealed altered bacterial morphology, with the bacteria displaying intramembranous edema and disrupted intracellular structural integrity (Fig.
3). As a membrane permeable compound, this innate characteristic of resveratrol may allow it to alter the bacterial membrane structure of
P. acnes and disrupt intracellular machinery.
Benzoyl peroxide was found to be highly cytotoxic to monocytes and keratinocytes, potentially explaining the irritation found with topical benzoyl peroxide regimens (Fig.
4). Resveratrol was significantly less cytotoxic, which may translate to decreased irritation in vivo. A pilot study investigating topical resveratrol treatment in acne found no cutaneous side effects from resveratrol [
16]. Additionally, one study demonstrated that macrophages treated with resveratrol maintained viability via a toll-like receptor 4 (TLR4)-dependant mechanism if also treated with lipopolysaccharide [
25], indicating that resveratrol may be less cytotoxic to cells in the presence of
P. acnes.
A combination therapy of resveratrol and benzoyl peroxide may allow for a significant reduction of the benzoyl peroxide concentration compared to current benzoyl peroxide-based treatments, minimizing side effects. However, this study was in vitro, which does not necessarily translate to success in the clinic. Concentrations used in vitro may not accurately reflect effective in vivo concentrations necessary for the treatment of acne vulgaris. In vivo studies are needed to evaluate the efficacy of resveratrol and benzoyl peroxide in combination for the treatment of acne vulgaris.
Conclusion
Resveratrol’s anti-inflammatory and antibacterial properties demonstrated here in vitro may address some of the pathogenic mechanisms in the formation of acne. Already, clinical studies have shown the beneficial effects of resveratrol in the treatment of acne [
16]. However, acne is a multifactorial disease, attributed also to sebum production [
26], which is not currently known to be addressed by resveratrol, and which may therefore limit its use as a monotherapy in the treatment of acne. Since resveratrol and benzoyl peroxide operate with different antibacterial kinetics and mechanisms, they may complement each other in a combination treatment in vivo, leading to enhanced clinical outcomes. Overall, the data in this study indicates that resveratrol may be a novel therapeutic option or useful adjuvant therapy for the treatment of acne vulgaris.
Acknowledgments
We are indebted to the Women’s Dermatologic Society Academic Research Grant for funding this study as well as to Ami Oren, Marianne Cilluffo, Nathalie Fernando, Julie Patel, and Elaheh Salehi for their invaluable contributions to data collection and analysis. This study and the article processing charges were supported in part by the Women’s Dermatologic Society Academic Research Grant and NIH R01 AR053542. All authors had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. All named authors meet the ICMJE criteria for authorship, take responsibility for the integrity of the work as a whole and have given final approval for the version to be published. This study was supported in part by the Women’s Dermatologic Society Academic Research Grant and NIH R01 AR053542.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (
https://creativecommons.org/licenses/by/4.0), which permits use, duplication, adaptation, distribution, and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.